Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
This Month's Featured Story The Often-Missed Corner of Healthcare That Wall Street Is LovingWritten by Nathan Reiff. Publication Date: 3/29/2026. 
Key Points - Numerous lab equipment stocks are down in the high-teens so far this year, but seemingly modest sales growth may hide fundamental strengths.
- These companies can present a more secure approach to the healthcare industry than some higher-risk alternatives.
- Still, headwinds including tariff impacts and inflation remain a concern.
- Special Report: Have $500? Invest in Elon's AI Masterplan
The healthcare industry is notoriously volatile—company fortunes can be made or broken on the success of a single product or the results of a clinical trial—and it's not uncommon for stocks in this sector to see some of the wildest spikes (and drops) across the market. Investors who want exposure to the healthcare space but are wary of that turbulence might consider a "picks and shovels" approach that focuses on companies providing essential equipment and services to the industry, rather than higher-risk pharmaceutical names. Lab equipment stocks are often overlooked by healthcare investors, even though some companies in this subindustry are among the largest in the space. Given the range of external factors that could affect healthcare in 2026—shifting subsidies, an aging population, inflation, the growing role of AI, and more—core lab equipment names may be especially attractive. The companies below are some major players worth a closer look. A Recent Dip Masks Thermo Fisher's Long-Term Strengths A former Pentagon and CIA advisor is flagging April 15 as a critical date for gold investors. He says the U.S. government is set to grant final authorization for mining operations at what he believes is the largest gold deposit in the world. The company behind it trades at just $2 per share and has largely flown under the radar. He believes early investors positioned before the announcement stand to benefit most. View his full analysis and see the details behind this gold play $182 billion life sciences solutions, diagnostics, and analytical instruments company Thermo Fisher Scientific (NYSE: TMO) has had a difficult start to 2026, with shares down more than 15% year-to-date (YTD) and the company recently slipping into TradeSmith's red zone for financial health. A good portion of that weakness may stem from tariffs and foreign-exchange (FX) volatility, which together shaved over 100 basis points from margins in 2025. There are, however, several reasons for optimism in Thermo Fisher's recent results. In Q4 2025, revenue rose to $12.2 billion, up 7% year-over-year (YOY), beating analyst expectations by about $250 million. Adjusted earnings per share (EPS) also topped estimates at $6.57. That momentum may reflect recent product introductions, including the Orbitrap Astral Zoom mass spectrometer and new bioreactor offerings. Thermo Fisher's diversified business model should help cushion it against external pressures. Even if 2026 guidance is tepid—revenue is expected to rise 4% to 6%—improving EBITDA margins and steady customer demand are positive offsets. Analysts remain largely favorable: 17 of 19 rate TMO a Buy or equivalent, and consensus estimates suggest more than 29% upside potential. Danaher's Business May Be Improving, Even as Guidance Remains Modest Danaher Corp. (NYSE: DHR) shares are down nearly 20% YTD, placing it in a similar position to Thermo Fisher. While 2026 guidance points to modest core revenue growth of roughly 3% to 6% YOY, the latest quarter included solid results: top- and bottom-line beats in Q4 and $5.3 billion in free cash flow for 2025. Two bright spots for 2026 are its bioprocessing business—which is expected to deliver high-single-digit revenue growth driven by strong monoclonal antibody demand—and diagnostics, which may benefit from FDA clearances. Equipment orders, which had been weak for an extended period, have begun to recover, providing another tailwind for sales. Analysts are relatively upbeat on DHR, projecting about 12.3% earnings growth over the next year and roughly 35% upside in the share price. Accordingly, 19 of 22 analyst ratings are Buys. Agilent's Biocare Purchase Could Be a Catalyst Agilent Technologies (NYSE: A) has lagged some peers: its latest earnings showed tepid 4.4% year-over-year revenue growth and slight misses on both revenue and earnings versus expectations. However, Agilent may have a growth catalyst in its acquisition of Biocare Medical, which strengthens its position in cancer diagnostics. Although the Biocare purchase cost nearly $1 billion, it could add recurring revenue in a high-demand area. Cancer diagnostics is often a higher-margin business than some of Agilent's existing operations and could help lift operating margins, which stood at 24.6% in the last quarter. Despite a roughly 17% YTD decline, analysts see about 42% upside for Agilent. Wall Street rates the stock a Moderate Buy overall, with 13 of 16 analysts recommending Buy or similar. | 
